Drug carrier and drug carrier kit for inhibiting fibrosis
US8178124B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2011 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | Sep 29, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T428/2982
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.